Home LiteratureArticle Details
PMID: 7879415 Published · ppublish English Journal Article

Self-replicating Semliki Forest virus RNA as recombinant vaccine.

Vaccine ·Vol. 12 ·No. 16 ·1994-12-00 ·Pages 1510-4

Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, Liljeström P

Abstract

Recombinant RNA based on the Semliki Forest virus (SFV) replicon was used to express the nucleoprotein of influenza virus in mice. Two strategies were employed to deliver the RNA. In the first, recombinant RNA was packaged into infectious suicide SFV particles which were used directly for immunization. The second approach involved injection of in vitro-synthesized RNA directly into the quadriceps muscle. Both approaches resulted in the generation of humoral responses with high antibody titres. Immunization with suicide particles showed that a strong, class I-restricted cytotoxic T-cell response can be obtained using only 100 infectious units. We conclude that the self-replicative recombinant SFV RNA may be quite useful as a nucleic acid vaccine.

MeSH Terms
Animals Mice Mice, Inbred BALB C RNA, Viral/genetics,immunology Semliki forest virus/genetics,immunology T-Lymphocytes, Cytotoxic/immunology Transfection/immunology Vaccines, Synthetic/genetics,immunology Viral Vaccines/genetics,immunology Virus Replication/genetics
Chemicals
RNA, Viral Vaccines, Synthetic Viral Vaccines
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Zhou X
Center for Biotechnology, Karolinska Institute, Huddinge, Sweden.
Berglund P
Rhodes G
Parker S E
Jondal M
Liljeström P
Article Info
Journal
Vaccine
Abbr.
Vaccine
ISSN
0264-410X
Published
1994-12-00
Pages
1510-4
Language
English
Region
Netherlands
NLM ID
8406899
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com